DBS denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for dbs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues Duplicate-Therapy Denials for Deep Brain Stimulation (DBS)

Deep brain stimulation is a neurosurgical intervention in which an implanted device delivers electrical stimulation to targeted brain structures to manage symptoms of conditions such as Parkinson's disease, essential tremor, dystonia, or obsessive-compulsive disorder. A duplicate-therapy denial from BCBS typically occurs when the plan's system detects that the member is already receiving a therapy it categorizes in the same clinical bucket — for example, an existing medication regimen for movement disorders, a prior neuromodulation device, or a prior DBS system already on record. The denial is almost always generated by automated claims-editing rules that flag apparent redundancy without examining clinical purpose.

## Why This Denial Is Appealable

DBS does not duplicate medication therapy — it serves a mechanistically distinct role, is indicated specifically for patients whose symptoms are inadequately controlled on optimized medical management, and may be the only remaining option for functional improvement. If the "duplicate" is a prior DBS device, the clinical picture (device end-of-life, lead revision, new indication, contralateral implant, replacement for malfunction) must be explained. BCBS is obligated under its medical policy to evaluate clinical context, not just billing codes.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe stated on your denial explanation of benefits (commonly 180 days). BCBS must respond within 30 days for pre-service or 60 days for post-service.
• Expedited appeal: Available for urgent or ongoing care situations; decision required within 72 hours.
• External review (ACA §2719 / ERISA §503): After final internal denial, you have approximately four months to request independent external review. The external reviewer applies clinical criteria independent of BCBS.

## Documentation to Gather

1. Diagnosis and symptom-severity documentation — neurologist or movement-disorder specialist notes quantifying symptom burden (motor scores, quality-of-life scales, functional assessments). 2. Prior therapy history — complete list of all medications tried, with doses, durations, and documented inadequate response or intolerance, showing that medical management has been optimized. 3. Explanation of clinical distinction — prescriber letter explaining why DBS is not duplicative of existing therapy and what distinct clinical goal it addresses. 4. Device/procedure specifics — if a prior DBS device exists, documentation of why a new procedure is needed (e.g., device failure, lead revision, new indication). 5. Relevant guideline support — reference to applicable specialty society guidance (e.g., from the Movement Disorder Society or relevant neurology societies) supporting DBS for the specific indication.

## Criteria-Mapping Structure

Obtain BCBS's medical policy for DBS and the FDA device labeling/approved indications. Map each requirement:

| Policy Requirement | Chart Evidence | |---|---| | Confirmed diagnosis meeting DBS indication | [diagnosis, date, specialist] | | Inadequate response to required prior therapies | [medications, durations, outcomes] | | DBS is not duplicative of current treatment | [prescriber explanation] | | Surgeon/center qualifications per policy | [surgeon credentials, center volume] |

A detailed prescriber letter that directly addresses the duplicate-therapy flag — explaining the clinical distinction between existing and proposed therapy — is essential to overturning this type of denial.